IP Library Granted Patent US 12703855
Granted Patent B2
US 12703855 · App. 18/454,183 · Granted Aug 11, 2026

Stem cell and tissue cultures and their products

Inventor: Raymond Mouzannar (Houston, TX)
Assignee: STEM CELL RESERVE LP
C12N5/0665A61L27/3834A61L27/3895C12N5/0605C12N2500/02C12N2502/137C12N2509/10C12N2513/00C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703855
App. No.
18/454,183
Granted
Aug 11, 2026
Kind
B2
Abstract

Methods and products obtained from the method for culturing stem cells and tissues using stem cells, cord tissue fragments, or stem cells, decellularized cord tissue fragments, or mixed cells from cord tissue or combinations thereof to amplify stem cells are described.

Claims (39)

1 . A method of cell culturing, said method comprising the following steps in order:

a) obtaining an umbilical cord tissue;

b) cleaning said umbilical cord tissue with a sterilizing agent;

c) mechanically dissociating said umbilical cord tissue into fragments;

d) liberating a cell mixture from said fragments to form a decellularized tissue matrix, wherein said cell mixture includes differentiated cells, stem cells and progenitor cells;

e) culturing i) said decellularized tissue matrix, or ii) said cell mixture, or both i) and ii) with serum, plasma or platelet lysate to form a combination, wherein said serum, plasma or platelet lysate is autologous or syngeneic or HLA-matched to at least 3 matched MHC loci and optionally gender-matched to said umbilical cord tissue;

f) culturing said combination under hypoxic conditions;

g) adding stem cells to said combination, wherein said stem cells are obtained from a biological source that is autologous or syngeneic or HLA matched at a same at least 3 matched MHC loci to said umbilical cord tissue; and

h) further culturing said combination under hypoxic conditions to amplify said stem cells.

2 . The method of claim 1 , further comprising step h2) isolating said amplified stem cells from said combination.

3 . The method of claim 1 , wherein one or more of:

(A) said fragments,

(B) said decellularized tissue matrix,

(C) said serum, plasma, or platelet lysate, or

(D) said cell mixture,

is a pooled HLA-matched product, each pooled portion of said HLA-matched product having the same at least 3 matched MHC loci.

4 . The method of claim 2 , wherein one or more of:

(A) said fragments,

(B) said decellularized tissue matrix,

(C) said serum, plasma, or platelet lysate,

(D) said cell mixture, or

(E) said stem cells,

is a pooled HLA-matched product, each pooled portion of said HLA-matched product having the same at least 3 matched MHC loci.

5 . The method of claim 1 , wherein step e) uses i) only.

6 . The method of claim 1 , wherein step e) uses ii) only.

7 . The method of claim 1 , wherein step e) uses i) and ii).

8 . The method of claim 2 , wherein step e) uses i) only.

9 . The method of claim 2 , wherein step e) uses ii) only.

10 . The method of claim 2 , wherein step e) uses i) and ii).

11 . A product produced by the method of claim 1 .

12 . A product produced by the method of claim 2 .

13 . A product produced by the method of claim 3 .

14 . A product produced by the method of claim 4 .

15 . A product produced by the method of claim 5 .

16 . A product produced by the method of claim 6 .

17 . A product produced by the method of claim 7 .

18 . A product produced by the method of claim 8 .

19 . A product produced by the method of claim 9 .

20 . A product produced by the method of claim 10 .